Immune function
Strong human evidenceTORC1 inhibition enhances immune function and reduces infections in the elderly
Mannick J.B., Morris M., Hockey H.-U.P. et al. · Science Translational Medicine, 2018
- Species
- Humans
- Design
- Randomized controlled trial
- Sample
- Over 600 older adults
What it found
Low-dose TORC1 inhibition over 16 weeks reduced the rate of laboratory-confirmed respiratory tract infections in older adults and upregulated antiviral gene expression.
Why it matters
A clinical outcome, not just a biomarker: fewer real infections. It is the strongest human evidence that this drug class does something useful for aging immunity at low doses.
How much weight this carries
Multiple randomized human trials with consistent, replicated results. In pets the effect is inferred from conserved biology and species-appropriate dosing.
This link runs a PubMed search on the paper’s exact title rather than a hard-coded DOI. It always resolves to the real record, and it cannot rot.
The content on this site is for informational purposes only and is not veterinary advice. These statements have not been evaluated by a food or drug regulatory authority and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a licensed veterinarian about your pet's health.